CytomX Therapeutics To Present Initial Translational Data From Ongoing Phase 1 Study Of CX-801 In Patients With Advanced Melanoma At SITC Annual Meeting
Benzinga Newsdesk 1 year ago
News
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -- Data supportive of CX-801's mechanism of action and the
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -
- Data supportive of CX-801's mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) -
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that initial translational data from the ongoing Phase 1 study of CX-801 in patients with advanced melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, being held in National Harbor, MD on November 7-9, 2025.